Pfizer, Anumana team up to develop AI algorithm for cardiac amyloidosis detection
Related Articles
Pfizer partners with healthtech company on AI-powered cardiovascular disease detection
Becker's Hospital Review: Pharmaceutical giant Pfizer has partnered with digital health company Anumana, a company founded in 2021 in collaboration with the Mayo Clinic Platform, to develop an artificial intelligence…December 16, 2022
Mayo Clinic launches two tech companies
Modern Healthcare: One of the companies, Anumana, is seeking clearance from the Food and Drug Administration to market an artificial-intelligence tool to detect heart conditions.April 13, 2021
Anumana Demonstrates Global Readiness with Receipt of ISO 13485 Certification
Anumana Demonstrates Global Readiness with Receipt of ISO 13485 CertificationCAMBRIDGE, Mass. – May 21, 2024 – Anumana, a leading AI-driven health technology company and portfolio company of nference, announced today…May 21, 2024
Anumana’s AI tool for pulmonary hypertension gets FDA breakthrough status
Medical Device Network: Anumana has received US Food and Drug Administration (FDA) Breakthrough Device Designation for its artificial intelligence (AI)-enhanced, electrocardiogram (ECG)-based Pulmonary Hypertension (PH) Early Detection Algorithm. The accurate,…May 24, 2022